Groups with PhRMA ties warn against drug-pricing proposals; patients learn how to be advocates; the U.K. will not cover Opdivo for head and neck cancer
Five things for pharma marketers to know: Thursday, October 27, 2016
New PhRMA CEO issues policy strategy; study assess patient response to immuno-oncology drugs; Twitter may be an effective way to talk about clinical trials
Five things for pharma marketers to know: Monday, February 8, 2016
February 8, 2016
3:00 pm
PhRMA and BIO ramp up ad spend for presidential election year; Super Bowl Sunday features three pharma ads; Pfizer solidifies leadership team
Five things for pharma marketers to know: Monday, September 28, 2015
PhRMA hires Ubl as CEO; two drugs report superior results in kidney-cancer trials compared to the standard of care; Novo Nordisk’s shares rise on Tresiba approval
Five things for pharma marketers to know: Tuesday, July 21
Physicians criticize pricing of Orkambi, Vertex’s new cystic-fibrosis drug; the EU approves Amgen’s PCSK9 inhibitor Repatha; PhRMA boosts lobbying spending in the second quarter
Five things for pharma marketers to know: Friday, April 17
The FDA approves generic Copaxone; AstraZeneca’s experimental lung-cancer drug demonstrates that it can delay disease progression; PhRMA CEO John Castellani to step down